Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma. / Jensen, Per; Blinkenberg, Morten; Pinborg, Lars Hageman.

In: Clinical Nuclear Medicine, Vol. 48, No. 8, 2023, p. E403-E404.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

Jensen, P, Blinkenberg, M & Pinborg, LH 2023, 'Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma', Clinical Nuclear Medicine, vol. 48, no. 8, pp. E403-E404. https://doi.org/10.1097/RLU.0000000000004739

APA

Jensen, P., Blinkenberg, M., & Pinborg, L. H. (2023). Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma. Clinical Nuclear Medicine, 48(8), E403-E404. https://doi.org/10.1097/RLU.0000000000004739

Vancouver

Jensen P, Blinkenberg M, Pinborg LH. Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma. Clinical Nuclear Medicine. 2023;48(8):E403-E404. https://doi.org/10.1097/RLU.0000000000004739

Author

Jensen, Per ; Blinkenberg, Morten ; Pinborg, Lars Hageman. / Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma. In: Clinical Nuclear Medicine. 2023 ; Vol. 48, No. 8. pp. E403-E404.

Bibtex

@article{23649f39f1774a99a5abf40b653a9223,
title = "Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma",
abstract = "This figure presents a comparison of molecular imaging of the translocator protein (TSPO) and contrast-enhanced MRI in 2 patients with tumefactive multiple sclerosis and glioblastoma, respectively. In the case of the tumefactive multiple sclerosis patient, TSPO uptake is primarily located centrally, while in the glioblastoma patient, TSPO uptake is predominantly situated peripherally to the central necrotic area. These findings suggest that TSPO imaging could be a noninvasive imaging technique for distinguishing between these 2 diagnoses. ",
keywords = "glioma, MRI, SPECT, translocator protein, tumefactive MS",
author = "Per Jensen and Morten Blinkenberg and Pinborg, {Lars Hageman}",
note = "Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",
year = "2023",
doi = "10.1097/RLU.0000000000004739",
language = "English",
volume = "48",
pages = "E403--E404",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams & Wilkins",
number = "8",

}

RIS

TY - JOUR

T1 - Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma

AU - Jensen, Per

AU - Blinkenberg, Morten

AU - Pinborg, Lars Hageman

N1 - Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2023

Y1 - 2023

N2 - This figure presents a comparison of molecular imaging of the translocator protein (TSPO) and contrast-enhanced MRI in 2 patients with tumefactive multiple sclerosis and glioblastoma, respectively. In the case of the tumefactive multiple sclerosis patient, TSPO uptake is primarily located centrally, while in the glioblastoma patient, TSPO uptake is predominantly situated peripherally to the central necrotic area. These findings suggest that TSPO imaging could be a noninvasive imaging technique for distinguishing between these 2 diagnoses.

AB - This figure presents a comparison of molecular imaging of the translocator protein (TSPO) and contrast-enhanced MRI in 2 patients with tumefactive multiple sclerosis and glioblastoma, respectively. In the case of the tumefactive multiple sclerosis patient, TSPO uptake is primarily located centrally, while in the glioblastoma patient, TSPO uptake is predominantly situated peripherally to the central necrotic area. These findings suggest that TSPO imaging could be a noninvasive imaging technique for distinguishing between these 2 diagnoses.

KW - glioma

KW - MRI

KW - SPECT

KW - translocator protein

KW - tumefactive MS

U2 - 10.1097/RLU.0000000000004739

DO - 10.1097/RLU.0000000000004739

M3 - Letter

C2 - 37314704

AN - SCOPUS:85164231558

VL - 48

SP - E403-E404

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 8

ER -

ID: 363282607